BOSTON, Oct. 3, 2014
/PRNewswire/ -- PAREXEL International Corporation (Nasdaq:
PRXL)("PAREXEL" or the "Company"), a global clinical research
organization, announced today that the Company has acquired all of
the outstanding equity securities of privately-owned ClinIntel, a
provider of clinical Randomization and Trial Supply Management
(RTSM) services, based in the United
Kingdom.
ClinIntel's offerings will be combined into the
ClinPhone® RTSM suite and are designed to make patient
randomization and clinical supply chain solutions more
efficient. Capabilities include advanced RTSM technologies
for planning, forecasting and supply chain eLogistics. The
offerings are particularly helpful in accelerating study start-up
timelines. The entire ClinPhone® RTSM suite will
be available through the Perceptive MyTrials® platform
and as a standalone solution, and both solutions will be available
through the Perceptive® Partner Program.
ClinIntel was founded in 2009, and works with biopharmaceutical
companies and contract research organizations. The company is
headquartered in Crawley, United
Kingdom. The acquisition was funded with existing cash, and
the impact of the acquisition on PAREXEL's Fiscal Year 2015 revenue
and earnings per share is not expected to be material. The
business will be integrated into the PAREXEL Informatics
segment.
Josef von Rickenbach, Chairman
and CEO of PAREXEL International stated, "As the use of technology
has expanded in the conduct of clinical research, PAREXEL has been
a leader in Randomization and Trial Supply Management. By
combining the trial supply management technologies from ClinIntel
with our existing ClinPhone solutions, we believe we have an
opportunity to further advance our position as a clinical
technology leader and grow market share by bringing enhanced speed,
efficiency, and simplicity to our RTSM offering."
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services organization, providing a broad range of
knowledge-based contract research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, medical
education and reimbursement. PAREXEL Informatics, Inc. provides
advanced technology solutions, including medical imaging, to
facilitate the clinical development process. Headquartered near
Boston, Massachusetts, PAREXEL
operates in 80 locations in 51 countries around the world, and has
approximately 15,560 employees. For more information about
PAREXEL International visit www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, Perceptive, Perceptive MyTrials,
and "Your Journey. Our Mission." are trademarks or registered
trademarks of PAREXEL International Corporation or its
affiliates.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ significantly from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the recent acquisitions of LIQUENT,
Inc. and HERON Group Ltd., Inc., or enter into new lines of
business; the impact on the Company's business of government
regulation of the drug, medical device and biotechnology
industry; consolidation within the pharmaceutical industry and
competition within the biopharmaceutical services industry; the
potential for significant liability to clients and third parties;
the potential adverse impact of health care reform; and the effects
of foreign currency exchange rate fluctuations and other
international economic, political, and other risks.
Such factors and others are discussed more fully in the section
entitled "Risk Factors" of the Company's Annual Report on Form 10-K
for the Fiscal Year ended June 30,
2014 as filed with the Securities and Exchange Commission on
August 20, 2014, which "Risk Factors"
discussion is incorporated by reference in this press
release. The Company specifically disclaims any obligation to
update these forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
CONTACTS:
Ingo Bank, Senior Vice President
and Chief Financial Officer
Jill
Baker, Corporate Vice President of Investor
Relations
+1-781-434-4118
Diana Martin, Vice President of Corporate
Communications
+1-781-434-5516
SOURCE PAREXEL International Corporation